Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve

Next Previous
Trial Profile

Evaluation of the Long Term Safety of the Use of Dabigatran Etexilate in Patients With a Bileaflet Mechanical Heart Valve

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism; Thrombosis
  • Focus Adverse reactions
  • Acronyms RE-ALIGN-EX
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 17 Dec 2013 Results published in the Annals of Internal Medicine.
  • 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 18 Feb 2013 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top